Diferencia entre revisiones de «Template:Cholecystitis Antibiotics»
(Add disease=Cholecystitis parameter to AntibioticDose calls - fixes aggregation page display issue) |
(Fix disease parameter: Acute calculous cholecystitis (canonical name, Cholecystitis redirects there)) |
||
| Línea 3: | Línea 3: | ||
====Uncomplicated==== | ====Uncomplicated==== | ||
''Pathogenicity of [[Enterococci]] remains unclear and specific coverage is not routinely suggested for community-acquired infections''<ref name="WSES 2016">Ansaloni L, et al. 2016 WSES guidelines on acute calculous cholecystitis. World Journal of Surgery. (2016) 11:25. DOI 10.1186/s13017-016-0082-5</ref> | ''Pathogenicity of [[Enterococci]] remains unclear and specific coverage is not routinely suggested for community-acquired infections''<ref name="WSES 2016">Ansaloni L, et al. 2016 WSES guidelines on acute calculous cholecystitis. World Journal of Surgery. (2016) 11:25. DOI 10.1186/s13017-016-0082-5</ref> | ||
*{{AntibioticDose|disease= | *{{AntibioticDose|disease=Acute calculous cholecystitis|drug=Ertapenem|dose=1g IV once daily|context=Uncomplicated}} OR | ||
*{{AntibioticDose|disease= | *{{AntibioticDose|disease=Acute calculous cholecystitis|drug=Metronidazole|dose=500mg IV q8hrs|context=Uncomplicated}} PLUS | ||
**{{AntibioticDose|disease= | **{{AntibioticDose|disease=Acute calculous cholecystitis|drug=Ciprofloxacin|dose=400mg IV q12 hrs|context=Uncomplicated}} OR | ||
**{{AntibioticDose|disease= | **{{AntibioticDose|disease=Acute calculous cholecystitis|drug=Levofloxacin|dose=750mg IV q24hrs|context=Uncomplicated}} OR | ||
**{{AntibioticDose|disease= | **{{AntibioticDose|disease=Acute calculous cholecystitis|drug=Ceftriaxone|dose=1g IV q24hrs|context=Uncomplicated}} | ||
====Complicated or Healthcare Associated==== | ====Complicated or Healthcare Associated==== | ||
''Examples of complication include severe [[sepsis]] or hemodynamic instability'' | ''Examples of complication include severe [[sepsis]] or hemodynamic instability'' | ||
*{{AntibioticDose|disease= | *{{AntibioticDose|disease=Acute calculous cholecystitis|drug=Vancomycin|dose=15-20mg/kg|context=Complicated/Healthcare Associated}} PLUS any of the following options | ||
'''Options:''' | '''Options:''' | ||
*{{AntibioticDose|disease= | *{{AntibioticDose|disease=Acute calculous cholecystitis|drug=Metronidazole|dose=500mg IV q8hrs|context=Complicated}} PLUS {{AntibioticDose|disease=Acute calculous cholecystitis|drug=Ciprofloxacin|dose=400mg IV q12hrs|context=Complicated}} | ||
*{{AntibioticDose|disease= | *{{AntibioticDose|disease=Acute calculous cholecystitis|drug=Piperacillin/Tazobactam|dose=4.5g IV q8hrs|context=Complicated}} | ||
*{{AntibioticDose|disease= | *{{AntibioticDose|disease=Acute calculous cholecystitis|drug=Imipenem/Cilastatin|dose=500mg IV q6hrs|context=Complicated}} | ||
*{{AntibioticDose|disease= | *{{AntibioticDose|disease=Acute calculous cholecystitis|drug=Doripenem|dose=500mg IV q8hrs|context=Complicated}} | ||
*{{AntibioticDose|disease= | *{{AntibioticDose|disease=Acute calculous cholecystitis|drug=Meropenem|dose=1g IV q8hrs|context=Complicated}} | ||
Revisión del 23:13 19 mar 2026
Most often isolated organisms are Escherichia coli, Klebsiella pneumonia, and anaerobes, especially Bacteroides fragilis
Uncomplicated
Pathogenicity of Enterococci remains unclear and specific coverage is not routinely suggested for community-acquired infections[1]
- Ertapenem 1g IV once daily OR
- Metronidazole 500mg IV q8hrs PLUS
- Ciprofloxacin 400mg IV q12 hrs OR
- Levofloxacin 750mg IV q24hrs OR
- Ceftriaxone 1g IV q24hrs
Complicated or Healthcare Associated
Examples of complication include severe sepsis or hemodynamic instability
- Vancomycin 15-20mg/kg PLUS any of the following options
Options:
- Metronidazole 500mg IV q8hrs PLUS Ciprofloxacin 400mg IV q12hrs
- Piperacillin/Tazobactam 4.5g IV q8hrs
- Imipenem/Cilastatin 500mg IV q6hrs
- Doripenem 500mg IV q8hrs
- Meropenem 1g IV q8hrs
- ↑ Ansaloni L, et al. 2016 WSES guidelines on acute calculous cholecystitis. World Journal of Surgery. (2016) 11:25. DOI 10.1186/s13017-016-0082-5